Profile data is unavailable for this security.
About the company
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. The Company’s clinical product candidate, losmapimod, is developed for the potential treatment of facioscapulohumeral muscular dystrophy (FSHD). Its other clinical product candidate is FTX-6058, which is developed for the treatment of certain hemoglobinopathies, including sickle cell disease (SCD). In addition to product candidate development, the Company has developed a drug discovery approach that it employs to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat known root causes of genetically defined rare diseases. The Company has developed pociredir, which is designed to elevate the level of fetal hemoglobin, or HbF, for the treatment of people with SCD.
- Revenue in USD (TTM)2.81m
- Net income in USD-97.34m
- Incorporated2015
- Employees76.00
- LocationFulcrum Therapeutics Inc26 Landsdowne StreetCAMBRIDGE 02139United StatesUSA
- Phone+1 (617) 651-8851
- Fax+1 (302) 655-5049
- Websitehttps://www.fulcrumtx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Theravance Biopharma Inc | 57.42m | -55.19m | 429.27m | 99.00 | -- | 2.00 | -- | 7.48 | -0.9704 | -0.9704 | 1.04 | 4.43 | 0.1161 | -- | 3.35 | 580,040.40 | -11.16 | -40.51 | -11.79 | -48.50 | -- | -- | -96.11 | -305.27 | -- | -- | 0.00 | -- | 11.84 | -0.9956 | 40.54 | -- | -19.24 | -- |
| Alto Neuroscience Inc | 0.00 | -36.31m | 432.83m | 63.00 | -- | -- | -- | -- | -1.42 | -1.42 | 0.00 | 2.73 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.1238 | -- | -- | -- | -31.02 | -- | -- | -- |
| Annexon Inc | 0.00 | -134.24m | 432.92m | 71.00 | -- | 1.49 | -- | -- | -1.78 | -1.78 | 0.00 | 3.20 | 0.00 | -- | -- | 0.00 | -46.07 | -44.06 | -49.49 | -46.93 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.43 | -- | 62.56 | -- |
| Neurogene Inc | 0.00 | -36.32m | 434.05m | 91.00 | -- | 2.33 | -- | -- | -29.21 | -29.21 | 0.00 | 14.51 | 0.00 | -- | -- | 0.00 | -21.46 | -32.70 | -23.85 | -34.73 | -- | -- | -- | -- | -- | -- | 0.0006 | -- | -- | -- | 36.90 | -- | 45.63 | -- |
| Entrada Therapeutics Inc | 129.01m | -6.69m | 445.21m | 159.00 | -- | 1.83 | -- | 3.45 | -0.2543 | -0.2543 | 3.86 | 7.25 | 0.3578 | -- | -- | 811,402.50 | -1.85 | -- | -2.47 | -- | -- | -- | -5.18 | -- | -- | -- | 0.00 | -- | -- | -- | 92.93 | -- | -- | -- |
| C4 Therapeutics Inc | 20.76m | -132.49m | 448.65m | 145.00 | -- | 1.61 | -- | 21.62 | -2.67 | -2.67 | 0.4181 | 4.07 | 0.0514 | -- | 3.13 | 143,144.80 | -32.82 | -25.91 | -36.80 | -29.45 | -- | -- | -638.34 | -292.35 | -- | -- | 0.00 | -- | -33.25 | 1.40 | -3.37 | -- | -8.68 | -- |
| PepGen Inc | 0.00 | -78.63m | 449.73m | 64.00 | -- | 3.05 | -- | -- | -3.30 | -3.30 | 0.00 | 4.55 | 0.00 | -- | -- | 0.00 | -43.62 | -- | -48.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.78 | -- | -- | -- |
| Editas Medicine Inc | 78.12m | -153.22m | 449.82m | 265.00 | -- | 1.28 | -- | 5.76 | -2.06 | -2.06 | 1.03 | 4.27 | 0.1542 | -- | 10.19 | 294,803.80 | -30.24 | -29.85 | -34.43 | -33.19 | -- | -- | -196.13 | -347.71 | -- | -- | 0.00 | -- | 296.32 | 19.59 | 30.49 | -- | -0.1477 | -- |
| Taysha Gene Therapies Inc | 15.45m | -111.57m | 452.58m | 52.00 | -- | 6.04 | -- | 29.29 | -1.37 | -1.37 | 0.1333 | 0.4008 | 0.1034 | -- | -- | 297,134.60 | -74.62 | -- | -111.87 | -- | -- | -- | -722.06 | -- | -- | -50.05 | 0.3529 | -- | 517.55 | -- | 32.80 | -- | -- | -- |
| Voyager Therapeutics Inc | 250.01m | 132.33m | 454.69m | 162.00 | 2.82 | 1.56 | 3.32 | 1.82 | 2.96 | 2.96 | 5.56 | 5.37 | 0.9792 | -- | 5.97 | 1,543,259.00 | 51.83 | 0.6378 | 70.85 | 0.8203 | -- | -- | 52.93 | 1.30 | -- | -- | 0.00 | 0.00 | 511.16 | 101.01 | 385.14 | -- | -5.43 | -- |
| Fulcrum Therapeutics Inc | 2.81m | -97.34m | 455.59m | 76.00 | -- | 1.93 | -- | 162.42 | -1.59 | -1.59 | 0.0458 | 3.80 | 0.0116 | -- | 1.68 | 36,907.89 | -40.19 | -50.55 | -42.88 | -55.91 | -- | -- | -3,470.05 | -1,189.10 | -- | -- | 0.00 | -- | -55.77 | -- | 11.41 | -- | -43.70 | -- |
| Travere Therapeutics Inc | 145.24m | -376.33m | 456.65m | 380.00 | -- | 2.25 | -- | 3.14 | -4.98 | -1.50 | 1.96 | 2.66 | 0.1988 | 1.40 | 7.68 | 382,205.30 | -51.50 | -36.95 | -65.94 | -44.77 | 92.12 | 95.92 | -259.11 | -165.79 | 3.41 | -- | 0.6526 | -- | 32.69 | -2.43 | -13.54 | -- | 16.49 | -- |
| Fate Therapeutics Inc | 63.53m | -160.93m | 462.88m | 181.00 | -- | 1.09 | -- | 7.29 | -1.63 | -1.63 | 0.6456 | 3.74 | 0.1049 | -- | 3.15 | 351,011.10 | -26.56 | -31.82 | -30.40 | -36.05 | -- | -- | -253.30 | -359.33 | -- | -- | 0.00 | -- | -34.03 | 68.05 | 42.88 | -- | 21.72 | -- |
| Third Harmonic Bio Inc | 0.00 | -30.82m | 463.33m | 30.00 | -- | 1.70 | -- | -- | -0.9461 | -0.9461 | 0.00 | 6.71 | 0.00 | -- | -- | 0.00 | -10.70 | -- | -10.91 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.32 | -- | -- | -- |
| Larimar Therapeutics Inc | 0.00 | -36.95m | 468.93m | 42.00 | -- | 3.95 | -- | -- | -0.8416 | -0.8416 | 0.00 | 1.86 | 0.00 | -- | -- | 0.00 | -33.24 | -42.22 | -36.56 | -47.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4.51 | -- | 8.71 | -- |
Data as of May 01 2024. Currency figures normalised to Fulcrum Therapeutics Inc's reporting currency: US Dollar USD
64.65%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 31 Dec 2023 | 11.61m | 18.75% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 5.68m | 9.18% |
| Suvretta Capital Management LLCas of 31 Dec 2023 | 5.52m | 8.91% |
| RTW Investments LPas of 31 Dec 2023 | 5.47m | 8.83% |
| Cowen & Co. LLCas of 31 Dec 2023 | 3.47m | 5.61% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 2.50m | 4.04% |
| Adage Capital Management LPas of 31 Dec 2023 | 1.51m | 2.43% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 1.44m | 2.32% |
| Jefferies Investment Advisers LLCas of 31 Dec 2023 | 1.43m | 2.31% |
| Citadel Advisors LLCas of 31 Dec 2023 | 1.40m | 2.27% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
